Tags

Type your tag names separated by a space and hit enter

[Use of inhaled tobramycin in patients with cystic fibrosis].
Ter Arkh. 2010; 82(8):76-8.TA

Abstract

The results of a few studies evaluating the efficacy and safety of nebulized tobramycin solution used in patients with cystic fibrosis have been published to date. Pulmonary deposition of inhaled tobramycin and its lung produced concentrations are rather high (10-25 times greater than the minimum suppressing concentration) and systemic absorption is extremely low. The treatment makes it possible to improve external respiratory function, to lower the colonization of the bronchi with Pseudomonas aeruginosa, and, in many cases, to achieve its eradication. Inhaled tobramycin reduces the sputum level of inflammatory cytokines in patients with cystic fibrosis, which slows down irreversible lung changes. Inhaled antibacterial therapy results in a reduction in the number of exacerbations, the frequency of admissions, and the need for systemic antibiotics.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

rus

PubMed ID

20873251

Citation

Chermenskiĭ, A G., and T E. Gembitskaia. "[Use of Inhaled Tobramycin in Patients With Cystic Fibrosis]." Terapevticheskii Arkhiv, vol. 82, no. 8, 2010, pp. 76-8.
Chermenskiĭ AG, Gembitskaia TE. [Use of inhaled tobramycin in patients with cystic fibrosis]. Ter Arkh. 2010;82(8):76-8.
Chermenskiĭ, A. G., & Gembitskaia, T. E. (2010). [Use of inhaled tobramycin in patients with cystic fibrosis]. Terapevticheskii Arkhiv, 82(8), 76-8.
Chermenskiĭ AG, Gembitskaia TE. [Use of Inhaled Tobramycin in Patients With Cystic Fibrosis]. Ter Arkh. 2010;82(8):76-8. PubMed PMID: 20873251.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Use of inhaled tobramycin in patients with cystic fibrosis]. AU - Chermenskiĭ,A G, AU - Gembitskaia,T E, PY - 2010/9/29/entrez PY - 2010/9/29/pubmed PY - 2010/12/14/medline SP - 76 EP - 8 JF - Terapevticheskii arkhiv JO - Ter Arkh VL - 82 IS - 8 N2 - The results of a few studies evaluating the efficacy and safety of nebulized tobramycin solution used in patients with cystic fibrosis have been published to date. Pulmonary deposition of inhaled tobramycin and its lung produced concentrations are rather high (10-25 times greater than the minimum suppressing concentration) and systemic absorption is extremely low. The treatment makes it possible to improve external respiratory function, to lower the colonization of the bronchi with Pseudomonas aeruginosa, and, in many cases, to achieve its eradication. Inhaled tobramycin reduces the sputum level of inflammatory cytokines in patients with cystic fibrosis, which slows down irreversible lung changes. Inhaled antibacterial therapy results in a reduction in the number of exacerbations, the frequency of admissions, and the need for systemic antibiotics. SN - 0040-3660 UR - https://www.unboundmedicine.com/medline/citation/20873251/[Use_of_inhaled_tobramycin_in_patients_with_cystic_fibrosis]_ L2 - http://babysfirsttest.org/newborn-screening/conditions/cystic-fibrosis-cf DB - PRIME DP - Unbound Medicine ER -